vs
艾伯维（ABBV）与NATURAL HEALTH TRENDS CORP（NHTC）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是NATURAL HEALTH TRENDS CORP的1704.6倍（$16.6B vs $9.7M）。艾伯维净利率更高（10.9% vs -6.0%，领先17.0%）。艾伯维同比增速更快（10.0% vs -10.1%）。艾伯维自由现金流更多（$4.9B vs $-964.0K）。过去两年艾伯维的营收复合增速更高（16.2% vs -5.6%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Sword Health是一家数字医疗企业，专注开发针对肌肉骨骼疾病、骨盆健康与损伤预防的物理治疗方案。该企业2015年由Virgílio Bento与Márcio Colunas在葡萄牙创立，将人工智能融入护理模式，提供数字化物理治疗服务。截至2024年，Sword Health已开展国际化运营，在美国、爱尔兰与葡萄牙均设有办公室。
ABBV vs NHTC — 直观对比
营收规模更大
ABBV
是对方的1704.6倍
$9.7M
营收增速更快
ABBV
高出20.2%
-10.1%
净利率更高
ABBV
高出17.0%
-6.0%
自由现金流更多
ABBV
多$4.9B
$-964.0K
两年增速更快
ABBV
近两年复合增速
-5.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $9.7M |
| 净利润 | $1.8B | $-588.0K |
| 毛利率 | 72.6% | 72.9% |
| 营业利润率 | 27.3% | -6.5% |
| 净利率 | 10.9% | -6.0% |
| 营收同比 | 10.0% | -10.1% |
| 净利润同比 | 8354.5% | -434.1% |
| 每股收益（稀释后） | $1.02 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVNHTC
| Q4 25 | $16.6B | $9.7M | ||
| Q3 25 | $15.8B | $9.5M | ||
| Q2 25 | $15.4B | $9.8M | ||
| Q1 25 | $13.3B | $10.7M | ||
| Q4 24 | $15.1B | $10.8M | ||
| Q3 24 | $14.5B | $10.7M | ||
| Q2 24 | $14.5B | $10.5M | ||
| Q1 24 | $12.3B | $11.0M |
净利润ABBVNHTC
| Q4 25 | $1.8B | $-588.0K | ||
| Q3 25 | $186.0M | $-431.0K | ||
| Q2 25 | $938.0M | $15.0K | ||
| Q1 25 | $1.3B | $122.0K | ||
| Q4 24 | $-22.0M | $176.0K | ||
| Q3 24 | $1.6B | $35.0K | ||
| Q2 24 | $1.4B | $173.0K | ||
| Q1 24 | $1.4B | $188.0K |
毛利率ABBVNHTC
| Q4 25 | 72.6% | 72.9% | ||
| Q3 25 | 66.4% | 73.7% | ||
| Q2 25 | 71.8% | 73.9% | ||
| Q1 25 | 70.0% | 73.6% | ||
| Q4 24 | 70.9% | 74.2% | ||
| Q3 24 | 70.9% | 74.1% | ||
| Q2 24 | 70.9% | 74.2% | ||
| Q1 24 | 66.7% | 73.4% |
营业利润率ABBVNHTC
| Q4 25 | 27.3% | -6.5% | ||
| Q3 25 | 12.1% | -5.2% | ||
| Q2 25 | 31.7% | -3.4% | ||
| Q1 25 | 28.0% | -3.2% | ||
| Q4 24 | -9.9% | -3.9% | ||
| Q3 24 | 26.5% | -2.6% | ||
| Q2 24 | 27.6% | -2.3% | ||
| Q1 24 | 22.7% | -3.3% |
净利率ABBVNHTC
| Q4 25 | 10.9% | -6.0% | ||
| Q3 25 | 1.2% | -4.5% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 9.6% | 1.1% | ||
| Q4 24 | -0.1% | 1.6% | ||
| Q3 24 | 10.8% | 0.3% | ||
| Q2 24 | 9.5% | 1.7% | ||
| Q1 24 | 11.1% | 1.7% |
每股收益（稀释后）ABBVNHTC
| Q4 25 | $1.02 | $-0.05 | ||
| Q3 25 | $0.10 | $-0.04 | ||
| Q2 25 | $0.52 | $0.00 | ||
| Q1 25 | $0.72 | $0.01 | ||
| Q4 24 | $-0.03 | $0.01 | ||
| Q3 24 | $0.88 | $0.00 | ||
| Q2 24 | $0.77 | $0.02 | ||
| Q1 24 | $0.77 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $28.9M |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $23.4M |
| 总资产 | $134.0B | $38.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVNHTC
| Q4 25 | $5.3B | $28.9M | ||
| Q3 25 | $5.7B | $32.0M | ||
| Q2 25 | $6.5B | $34.2M | ||
| Q1 25 | $5.2B | $41.9M | ||
| Q4 24 | $5.6B | $43.9M | ||
| Q3 24 | $7.3B | $46.3M | ||
| Q2 24 | $13.2B | $48.7M | ||
| Q1 24 | $18.1B | $54.4M |
总债务ABBVNHTC
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVNHTC
| Q4 25 | $-3.3B | $23.4M | ||
| Q3 25 | $-2.6B | $26.1M | ||
| Q2 25 | $-183.0M | $28.9M | ||
| Q1 25 | $1.4B | $30.9M | ||
| Q4 24 | $3.3B | $32.9M | ||
| Q3 24 | $6.0B | $35.3M | ||
| Q2 24 | $6.8B | $37.3M | ||
| Q1 24 | $8.0B | $39.4M |
总资产ABBVNHTC
| Q4 25 | $134.0B | $38.4M | ||
| Q3 25 | $133.9B | $42.3M | ||
| Q2 25 | $137.2B | $45.2M | ||
| Q1 25 | $136.2B | $53.2M | ||
| Q4 24 | $135.2B | $55.4M | ||
| Q3 24 | $143.4B | $58.3M | ||
| Q2 24 | $141.9B | $61.5M | ||
| Q1 24 | $148.9B | $67.6M |
负债/权益比ABBVNHTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $-959.0K |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $-964.0K |
| 自由现金流率自由现金流/营收 | 29.4% | -9.9% |
| 资本支出强度资本支出/营收 | 2.0% | 0.1% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $-6.1M |
8季度趋势，按日历期对齐
经营现金流ABBVNHTC
| Q4 25 | $5.2B | $-959.0K | ||
| Q3 25 | $7.0B | $113.0K | ||
| Q2 25 | $5.2B | $-5.6M | ||
| Q1 25 | $1.6B | $484.0K | ||
| Q4 24 | $7.0B | $88.0K | ||
| Q3 24 | $5.4B | $-436.0K | ||
| Q2 24 | $2.3B | $-3.6M | ||
| Q1 24 | $4.0B | $549.0K |
自由现金流ABBVNHTC
| Q4 25 | $4.9B | $-964.0K | ||
| Q3 25 | $6.6B | $70.0K | ||
| Q2 25 | $4.9B | $-5.6M | ||
| Q1 25 | $1.4B | $468.0K | ||
| Q4 24 | $6.8B | $68.0K | ||
| Q3 24 | $5.2B | $-443.0K | ||
| Q2 24 | $2.0B | $-3.6M | ||
| Q1 24 | $3.8B | $538.0K |
自由现金流率ABBVNHTC
| Q4 25 | 29.4% | -9.9% | ||
| Q3 25 | 42.1% | 0.7% | ||
| Q2 25 | 31.7% | -57.5% | ||
| Q1 25 | 10.5% | 4.4% | ||
| Q4 24 | 44.7% | 0.6% | ||
| Q3 24 | 35.9% | -4.1% | ||
| Q2 24 | 14.0% | -34.2% | ||
| Q1 24 | 31.3% | 4.9% |
资本支出强度ABBVNHTC
| Q4 25 | 2.0% | 0.1% | ||
| Q3 25 | 2.4% | 0.5% | ||
| Q2 25 | 1.7% | 0.0% | ||
| Q1 25 | 1.8% | 0.1% | ||
| Q4 24 | 1.9% | 0.2% | ||
| Q3 24 | 1.7% | 0.1% | ||
| Q2 24 | 1.7% | 0.2% | ||
| Q1 24 | 1.6% | 0.1% |
现金转化率ABBVNHTC
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | -375.67× | ||
| Q1 25 | 1.27× | 3.97× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | 3.49× | -12.46× | ||
| Q2 24 | 1.66× | -20.62× | ||
| Q1 24 | 2.95× | 2.92× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
